These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37408075)

  • 1. Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.
    Dubey D; Roy M; Shah TH; Bano N; Kulshrestha V; Mitra S; Sangwan P; Dubey M; Imran A; Jain B; Velmurugan A; Bakthavatchalam YD; Veeraraghavan B
    Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):55. PubMed ID: 37408075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.
    Tirlangi PK; Wanve BS; Dubbudu RR; Yadav BS; Kumar LS; Gupta A; Sree RA; Challa HPR; Reddy PN
    Antimicrob Agents Chemother; 2023 Jun; 67(8):e0050023. PubMed ID: 37314343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
    Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
    Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing
    Egge SL; Lewis JS; Hakki M
    Antimicrob Agents Chemother; 2023 Aug; 67(8):e0066323. PubMed ID: 37395652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
    Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
    Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M
    J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcending the challenge of evolving resistance mechanisms in
    Hujer AM; Marshall SH; Mack AR; Hujer KM; Bakthavatchalam YD; Umarkar K; Palwe SR; Takalkar S; Joshi PR; Shrivastava R; Periasamy H; Bhagwat SS; Patel MV; Veeraraghavan B; Bonomo RA
    mBio; 2023 Dec; 14(6):e0111823. PubMed ID: 37889005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
    Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
    Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222).
    Soman R; Sirsat R; Sunavala A; Punatar N; Mehta J; Rodrigues C; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2024 Feb; ():. PubMed ID: 38416290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.
    Moya B; Bhagwat S; Cabot G; Bou G; Patel M; Oliver A
    J Antimicrob Chemother; 2020 Jun; 75(6):1474-1478. PubMed ID: 32083659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
    Khan Z; Iregui A; Landman D; Quale J
    J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.